Ascendis Pharma/$ASND
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Ticker
$ASND
Sector
Primary listing
Employees
1,189
Headquarters
Hellerup, Denmark
Website
Ascendis Pharma Metrics
BasicAdvanced
$15bn
25.74
$9.34
-
-
Price and volume
Market cap
$15bn
52-week high
$250.27
52-week low
$216.22
Financial strength
Current ratio
0.996
Quick ratio
0.683
Long term debt to equity
79.124
Total debt to equity
183.753
Interest coverage (TTM)
-0.06%
Profitability
EBITDA (TTM)
-11.886
Gross margin (TTM)
89.04%
Net profit margin (TTM)
57.28%
Operating margin (TTM)
-0.84%
Effective tax rate (TTM)
396.50%
Revenue per employee (TTM)
$848,690
Management effectiveness
Return on assets (TTM)
-0.60%
Return on equity (TTM)
332.65%
Valuation
Price to earnings (TTM)
25.745
Price to revenue (TTM)
14.58
Price to book
30.61
Price to tangible book (TTM)
30.85
Price to free cash flow (TTM)
280.552
Free cash flow yield (TTM)
0.36%
Free cash flow per share (TTM)
0.857
Growth
Revenue change (TTM)
134.82%
Earnings per share change (TTM)
-237.93%
3-year revenue growth (CAGR)
123.13%
10-year revenue growth (CAGR)
61.23%
3-year earnings per share growth (CAGR)
-7.55%
10-year earnings per share growth (CAGR)
13.67%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ascendis Pharma stock?
Ascendis Pharma (ASND) has a market cap of $15B as of May 17, 2026.
What is the P/E ratio for Ascendis Pharma stock?
The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 25.74 as of May 17, 2026.
Does Ascendis Pharma stock pay dividends?
No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of May 17, 2026.
When is the next Ascendis Pharma dividend payment date?
Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ascendis Pharma?
Ascendis Pharma (ASND) does not currently have a Beta indicator.